{"ticker": {"uuid": "5df610fa-6629-4e41-967b-95c2a80fd757", "symbol": "BDTX", "name": "Black Diamond Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE51UjdLRkdobXBvdUN6eDhqaDdlWjJOUUFGdk0yRW1jTktRTHdvM2lWVmtoSkdYN21CMnlsZmctSTloRzVKWEN6N0dvYjE1ZW1sOU83cWtJVzBaRUNxSE00?oc=5", "source_name": "ChartMill", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary", "summary": "This article summarizes Black Diamond Therapeutics' 24th Annual Needham Virtual Healthcare Conference, held on December 27, 2025. Key highlights include the development of oral oncology therapies, particularly BDTX-1535 for non-small cell lung cancer (NSCLC) and glioblastoma, wit", "url": "https://quartr.com/events/black-diamond-therapeutics-bdtx-24th-annual-needham-virtual-healthcare-conference_Fe5VYqZG", "source_name": "Quartr", "published_at": "2026-07-13T06:41:43", "published_display": "13 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment", "summary": "T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 4,028,202 shares of Black Diamond Therapeutics I (BDTX) common stock, which represents a 7.0% stake as of June 30, 2026. The filing specifies that T. Rowe Price holds ", "url": "https://www.stocktitan.net/sec-filings/BDTX/schedule-13g-a-black-diamond-therapeutics-inc-amended-passive-investm-2867a64d67fb.html", "source_name": "Stock Titan", "published_at": "2026-07-08T15:39:17", "published_display": "08 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNN050U0RGVnNjX0dDNTJzOE4xaEM2Q2FxQ3BFMU5VV2laaVBrN3hfMjRwODFCMlJDUGZpREZFZHlzZGgyZGxDM3VDVFBnT3U4VzF1eWZBUUlEdmVNSTVod2NyS0VKYUZUSWlFeWVEc3FqVmI1aTctbl95cXJuSWZ1ZXpNb3BmeVlnT1pJeUpQS0dmcWpmaEJwWmdxdkhOSTk3dkFFS2ZaNmk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article analyzes Black Diamond Therapeutics Inc.'s (BDTX) financial performance, focusing on its profitability and market position. It highlights the company's undefined gross, operating, and net margins, alongside a Return on Equity (ROE) of -35.16%. The analysis also inclu", "url": "https://intellectia.ai/en/stock/BDTX/financials", "source_name": "Intellectia AI", "published_at": "2026-07-04T04:39:55", "published_display": "04 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 32, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDTX SEC Filings - Black Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Black Diamond Therapeutics (BDTX) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms (Form 4). Recent filings highlight director stock compensation in lie", "url": "https://www.stocktitan.net/sec-filings/BDTX/page-4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:10:19", "published_display": "01 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali", "summary": "This article reports a statement of changes in beneficial ownership of securities for Director Behbahani Ali at Black Diamond Therapeutics. This indicates a filing related to insider trading or changes in stock holdings by a company director.", "url": "https://www.moomoo.com/news/notice/306711005/black-diamond-therapeutics-4-statement-of-changes-in-beneficial-ownership", "source_name": "Moomoo", "published_at": "2026-07-01T10:12:12", "published_display": "01 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash", "summary": "This document is a statement of changes in beneficial ownership of securities for Raman Prakash, a Director at Black Diamond Therapeutics. It details changes in his holdings, as required by regulatory bodies.", "url": "https://www.moomoo.com/news/notice/306710932/black-diamond-therapeutics-4-statement-of-changes-in-beneficial-ownership", "source_name": "Moomoo", "published_at": "2026-06-30T22:09:24", "published_display": "30 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity", "summary": "Black Diamond Therapeutics director Raman Prakash received a grant of 40,000 stock options with an exercise price of $1.71 per share, expiring on June 25, 2036. The options will vest fully on the earlier of June 26, 2027, or the company's next annual meeting, provided Prakash rem", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-624b4014d370.html", "source_name": "Stock Titan", "published_at": "2026-06-30T09:09:09", "published_display": "30 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond (BDTX) director awarded 40,000 stock options at $1.71", "summary": "Black Diamond Therapeutics director Ali Behbahani was granted 40,000 stock options at an exercise price of $1.71 per share, set to expire on June 25, 2036. These compensation awards will vest on the earlier of June 26, 2027, or the company's next annual meeting, provided Behbahan", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-49422efa8e65.html", "source_name": "Stock Titan", "published_at": "2026-06-29T22:09:24", "published_display": "29 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) 2026 meeting backs directors, auditor and annual say-on-pay", "summary": "Black Diamond Therapeutics (BDTX) held its 2026 annual shareholder meeting where stockholders elected Shannon Campbell and Kapil Dhingra as Class III directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending Decembe", "url": "https://www.stocktitan.net/sec-filings/BDTX/8-k-black-diamond-therapeutics-inc-reports-material-event-518692486751.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:10:24", "published_display": "29 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com", "summary": "This article reports on a Form 4 filing for Black Diamond Therapeutics Inc. on June 29. It includes the stock symbol BDTX and its current performance (+2.34%). The content primarily shows a stock market overview with various financial data.", "url": "https://ca.investing.com/news/stock-market-news/form-4-black-diamond-therapeutics-inc-for-29-june-93CH-4712536", "source_name": "Investing.com Canada", "published_at": "2026-06-29T21:09:09", "published_display": "29 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71", "summary": "Samarth Kulkarni, a director at Black Diamond Therapeutics (BDTX), was granted stock options for 40,000 shares of common stock with an exercise price of $1.71 per share. These options are set to vest on the earlier of June 26, 2027, or the company's next annual meeting, contingen", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-be22c0474bdb.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:09:09", "published_display": "29 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) awards 40,000-share option grant", "summary": "Black Diamond Therapeutics director Shannon Campbell was granted stock options for 40,000 shares of common stock with an exercise price of $1.71 per share, expiring on June 25, 2036. The options will vest on the earlier of June 26, 2027, or the company\u2019s next annual meeting, prov", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-d70612b418a7.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:09:09", "published_display": "29 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 2000 Index", "summary": "Black Diamond Therapeutics, Inc. (NasdaqGS:BDTX) has been added to the Russell 2000 Index, a significant development for the clinical-stage oncology company. This inclusion follows several recent updates, including positive Phase 2 results for their drug Silevertinib and addition", "url": "https://www.marketscreener.com/news/black-diamond-therapeutics-inc-nasdaqgs-bdtx-added-to-russell-2000-index-ce7f5fdfda8cf021", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:40:54", "published_display": "29 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark", "summary": "Black Diamond Therapeutics, Inc. (NasdaqGS:BDTX) has been added to the Russell 2000 Value Benchmark, as reported on June 29, 2026. This inclusion is part of a series of recent index additions and removals for the company, including being added to the Russell 2000 Index and Russel", "url": "https://www.marketscreener.com/news/black-diamond-therapeutics-inc-nasdaqgs-bdtx-added-to-russell-2000-value-benchmark-ce7f5fdfd88afe21", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:23:00", "published_display": "29 Jun 2026 11:23", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 3000E Index", "summary": "Black Diamond Therapeutics, Inc. (NasdaqGS: BDTX) has been added to the Russell 3000E Index. The company, a clinical-stage oncology firm, focuses on developing MasterKey therapies for various oncogenic mutations in cancer patients, including its BDTX-1535 drug for NSCLC and gliob", "url": "https://www.marketscreener.com/news/black-diamond-therapeutics-inc-nasdaqgs-bdtx-added-to-russell-3000e-index-ce7f5fdedd81f420", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:40:08", "published_display": "29 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Black Diamond Therapeutics, Inc. \u2013 NASDAQ:BDTX", "summary": "The article focuses on the enterprise value to EBITDA forward for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). It indicates that the company's market is currently closed with no trades. The content primarily lists navigational elements and financial data sources provided by v", "url": "https://www.tradingview.com/symbols/NASDAQ-BDTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:40:08", "published_display": "29 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Black Diamond Therapeutics, Inc. \u2013 BOATS:BDTX", "summary": "The article focuses on the \"Price to book forward\" metric for Black Diamond Therapeutics, Inc. (BDTX), listed on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data page from TradingView, displaying no actual data but providing context for where suc", "url": "https://www.tradingview.com/symbols/BOATS-BDTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:54", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Black Diamond Therapeutics, Inc. \u2013 BOATS:BDTX", "summary": "This article provides financial information for Black Diamond Therapeutics, Inc. (BDTX) via TradingView. It specifically focuses on the company's price to sales forward metric. The content is part of a larger financial data platform.", "url": "https://www.tradingview.com/symbols/BOATS-BDTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:38", "published_display": "26 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) AGM 2026 Summary", "summary": "This article provides a summary of Black Diamond Therapeutics (BDTX) 2026 Annual General Meeting (AGM). The virtual meeting addressed formal business, corporate governance, and voting procedures, confirming a quorum with nearly 78% shareholder representation. The summary highligh", "url": "https://quartr.com/events/black-diamond-therapeutics-inc-bdtx-agm-2026_Fe5VPE4o", "source_name": "Quartr", "published_at": "2026-06-26T17:10:41", "published_display": "26 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Black Diamond Therapeutics, Inc. \u2013 NASDAQ:BDTX", "summary": "This article displays the \"Price to sales forward\" metric for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). The content appears to be a stub or a section from a larger financial data platform, showing the stock ticker and market information without detailed financial figures o", "url": "https://www.tradingview.com/symbols/NASDAQ-BDTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:57", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Black Diamond Therapeutics, Inc. \u2013 NASDAQ:BDTX", "summary": "This article focuses on the enterprise value to EBIT forward ratio for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The content highlights the specific financial", "url": "https://www.tradingview.com/symbols/NASDAQ-BDTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:42:16", "published_display": "26 Jun 2026 02:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Black Diamond Therapeutics, Inc. \u2013 BOATS:BDTX", "summary": "This article focuses on the price-to-earnings forward metric for Black Diamond Therapeutics, Inc. (BDTX), listed under the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data page from TradingView, providing an overview of the company's financial inform", "url": "https://www.tradingview.com/symbols/BOATS-BDTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:42:16", "published_display": "26 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Black Diamond Therapeutics Inc For: 22 June By Investing.com", "summary": "This article announces the filing of Form 4 for Black Diamond Therapeutics Inc. on June 22nd, as reported by Investing.com. It is a brief, one-sentence news piece from an investing news platform. The content primarily focuses on the regulatory filing for the specified company on ", "url": "https://ng.investing.com/news/stock-market-news/form-4-black-diamond-therapeutics-inc-for-22-june-93CH-2568528", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T06:39:38", "published_display": "23 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ali Behbahani of Black Diamond (NASDAQ: BDTX) receives 8,961-share award", "summary": "Ali Behbahani, a director at Black Diamond Therapeutics (NASDAQ: BDTX), was granted 8,961 shares of common stock valued at $1.66 per share. This award was part of the company's non-employee director compensation policy, allowing him to elect stock in lieu of cash for his annual b", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-c7ce2d383942.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:40:20", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Black Diamond Therapeutics Inc (BDTX) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The article also presents current stock perf", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:07", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Inc (BDTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "Black Diamond Therapeutics Inc (BDTX) currently has a price momentum score of 6.58, ranking 228th in its industry. The stock is trading between a resistance level of 3.21 and a support level of 0.90, making it suitable for range-bound swing trading. Technical indicators and movin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdtx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:41", "published_display": "17 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes the valuation of Black Diamond Therapeutics Inc (BDTX), noting its current valuation score of 6.68, which places it in the lower rankings within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.19, indicating a signi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T15:39:55", "published_display": "16 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path", "summary": "The article discusses Black Diamond Therapeutics' promising lung cancer data for its drug Silevertinib. The company is evaluating its FDA approval pathway based on these results.", "url": "https://www.msn.com/en-us/health/other/black-diamond-therapeutics-touts-silevertinib-lung-cancer-data-eyes-fda-path/ar-AA24Z84P", "source_name": "MSN", "published_at": "2026-06-13T01:40:00", "published_display": "13 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Stock Outlook After Q1 Beat and Cash Runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRFZIZGU5TkVfLTUxbnRYVWlDcjRnLTRvbnVrUF85VUV2MHdtdG5COV9XY2ZaYVlSbHpzN0lldmUyWS1UaVZ5aHlmQkU4OThaQXpxRVk2VUo5ZUJ3YXZ3ckJ0Mlk1RXhhYm1fOUN6R3BQMHpLc2dWYk1OVWJORWljcTBKZm9qU243Z3RnSXNVeHpJMjZLOXJweTdJaw?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/black-diamond-therapeutics-participate-jefferies-120000523.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T12:00:00+00:00", "published_display": "22 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study", "summary": "", "url": "https://finance.yahoo.com/m/3bca08cd-03ae-38d2-b343-d6661fcfbf84/black-diamond-therapeutics.html", "source_name": "MarketBeat", "published_at": "2026-05-21T23:09:11+00:00", "published_display": "21 May 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/black-diamond-therapeutics-announces-positive-211300750.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:13:00+00:00", "published_display": "21 May 2026 21:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Announces Encouraging Phase 2 Trial Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxOV3F4Ulpkcl80eEt6TTVxUWVVSVh1ZzZZeEg2akNoT0V3Qk02anp5SWpqSkplOHBKOFByM1E4OUhEcW01XzZXazRiRm9YVExXY0k4eWdyOHpCNzJENkRWY2NtdTdsZUtmOUlEckxSVjYyT1Rtb1NIbGZOOG10ajVCelExRms0dHFQeTZkWGhtNkpmNkxhYlF2S1NoRmdWM3FEcmlNd0FTbkZmYnBuNElkY1BpMmdZaE8zaXp3RnEtd2FMc2ZkbVdNeW1vTW9FV0pOa2ZUSXU1S1NESlVYclhjTkExd040QWE5UkRlMkRWbFlBZlVHbnJuay1mamNQQ2pjWHRNSWZwUzhCaTNkTVFR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/black-diamond-therapeutics-host-webcast-120000895.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T12:00:00+00:00", "published_display": "19 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNdjZCVlZ4Y0RfR1N0RFlJaFY3QXpES1NrRDhBbkxCNFFEeXNLNjhCUkJwTUtnUTg2MnlKMG9CRVhkT1IyZW9VVXJWdThVVkhVY0I4aC1jV0lTRksxdU1xRzBET1N1Sm5JTnJFSWdsNkJyQ2xEcFhIejNRVXdLQzJwUklfQnBqOU5EXy0tWmdXN2FmdGlhY3ZNNXp4ZHlsMW1NOGphWEZ3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZ2hGREgxYVJWVk1JQ1hsLXdqZUNQeXk5WEJrS2VzTkluVjAtTnpYS0NqWFluU3JQTzJWNFhiUmNXa285eV9hN2wwNDJxWHNfbUpSUXE5UkVmV0Z3a3JwUWE3STJseWJuTC03UzhkLUVjSGRCclRUT2FoenFOUTl0RGdQeEpOaHNaSk9TSzBhb3NjcmZYOUNxa1NKUGZkSjFQNjZ0bmFrVlZUUmdDbnc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Black Diamond Therapeutics Announces Multiple Presentations on Silevertinib at 2026 ASCO Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPN2VyLTRDeWp6MUhBUjBCMmZUOFdjdmY0RWxSMG1FMjh2WUl2VE55VkNLenJaSC1TVG5zVC1XTW9pbHJhZXpWNUFDVWJsY3U4UWp0aHlPdDB4a0ZNdmhrUzFrQ3NabktNNWtISmY4QzZlY19zUlRHRXYwbjctWnRqY2pfM0VoNVM4VmdXdHR4R2w1VWRyMUFHbWVlN05rOFpLUGxGVjlfeERaUEhoZkFaUHF5a2JPb1Fpa28wZlNrcFY4NzUxaGtFRUgyd1pKVmxTeXc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lung cancer drug data from Black Diamond gets ASCO oral slot", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPQjNrbVVHZjZjM2hoVFhLOW5ReXJRTzI1UXZkOTNkNUZSX3lwMEZrVHRBUFY2M292bGhIdU4xRmRKY1FOaXpvUUNCWFZpN0NZdTJmVGcyR1FzS3NTel9lNWpjazhkZ2R0RDdPX3J0R1FFTXpOYUM5bkJfd0lEa0hsQzR2Z051aXlWRUhnMWtQVTBkV19sem5Xczg5V1h5dVF5T21MUVU5emdiZ3ZreFF5cEFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNQW9IRWttYWtPT1FXMkdORFQ4SkpBd1ZheXBoZERoTy03blRJT1J5bnZtc3N3T1hqS0I5TFdYX3A2djVOLTFBVWlGaUxMQUZqYU1VVTBaTXh1cTZCV05EVFk2eVhXUjhPYjNNR3BXZWxsd1c3MEY0aXhaOTlTbHF6bzdFcjFzNGFWVDdQM0FVdVFlM2lD?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOQW9hdGdPTVh3bTc1YW9UcGNFV1NSX3hTc01GZDl0N29Ha3RyTWRGdzBqODdqR3EtczR5UGJnbFE3QzBQMnNTWncyX1NXWVhZTm9zZUR6ZDJPQUxKTExnZkJlbnE1WXNhOTR4WEFocXc4ak9QQ2hlLWFsbkgzRVFDTHp6TGc3dlJmUFA5YkNSNkhhSXJ1SE9xWUdZYVF5bms0bVlkU0dTdnJlRU52Q2lWWA?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNMmthcTJ6TzlVdm5DckFfbEF6WkdWV21KaE9jcW53U0JfY29JeUgwTkZXRGhYWVRMa2dyV05sWGRYcVc3V1Yyb2d5WnVLbXpuRXBITndzVDdxelp0bFVuLXM2VHZ3UVEzOFI3SUUtTDlJTXphakRPVVVQZ0lGYzBzSzlLM3ZfOWZC?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Black Diamond (BDTX) a New Strong Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPa01mX3FPZzJqZV92a0JjMEdNTG5CWEVhUGZZemNwc28yWWxfNlBCdmE1WncyOHVsM19GYzNIbmhsTS10bmxCelU5V1hXMmZpVGVNU1RWZlRJUlpCTFZVT3FBS2lEVmQ5dUtDTEZZemhQQ2lINHYxbnlyQzhKb0c4US1OOA?oc=5", "source_name": "Market source", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5nVmVxNVVNbTYwaGN1UlJMd0lGeEM5RkF1MEc1RmxmZjdsbVYwdno5bzFlMlhsYlBCWXJ4OWt0UFpRRU5OS1B6Uy1tcTJPdUxFWWR6cUJ4Q3lUZTZ0RlY4Q2ZSMTQ4N0luM3MwZ0g2LVA?oc=5", "source_name": "Market source", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNaUxIaXUtSUJRRDA5dlIxdXgwdEZUMkZTMHBoZjVTWjVEVkdGM1RmazhTTVZESzBTbEJNSWVnUzk0cFhrUlZoTHJKY1ZNT08tWHNCQW9USVBvYzdMdmdiUW5hVDlST1BQQXh4VkgzRXVwTlpReUtIWGxZeWFHODBFTWEtbkhfZlk1blRtRA?oc=5", "source_name": "Market source", "published_at": "2025-08-18T07:00:00+00:00", "published_display": "18 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFB5LWNvTGpCRW5vbTQ0NFl2MWR4Um1tV3NOakVDY2FKNFRDS2NqNE8tTXBsWXRmY2IzYlY3cGpac1c3djRmLTlSUWFtVUk5amtObTM0R3B1TzJQeFdGY0xuZURHZzN2QXV1?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T17:05:23+00:00", "published_display": "09 Jul 2025 17:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBSWVVRWTNEN0FsNmJickxrVkRiUGR0eDIwSkF1Sm5jMVVTUklrRURfeXRkWkZJaFludU81dE9RTVZGcTlZR2ZlSnVOLVgySkxVREV3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:15:37+00:00", "published_display": "25 Apr 2025 01:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics: Is Now the Time to Buy or Run Away?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQR2NpbUtENURkYmRnVXhKZmtqSUdURWxXSTVNNEFpUmhmMXFMX2dSdDRzZHFjcElhaXVTNzdtMXlVQUlkbWlZZHJNdFB1Tm1odHpxMk90cGt2NFdBVnFQVzBWeGsydFVFM3BhR20xaUxsT0JLZmo4cnFLR2VDeThZRmRxdFVYZnVLTGRxOG53YVlGUQ?oc=5", "source_name": "timothysykes.com", "published_at": "2024-09-23T07:00:00+00:00", "published_display": "23 Sep 2024 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE51UjdLRkdobXBvdUN6eDhqaDdlWjJOUUFGdk0yRW1jTktRTHdvM2lWVmtoSkdYN21CMnlsZmctSTloRzVKWEN6N0dvYjE1ZW1sOU83cWtJVzBaRUNxSE00?oc=5", "source_name": "ChartMill", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary", "summary": "This article summarizes Black Diamond Therapeutics' 24th Annual Needham Virtual Healthcare Conference, held on December 27, 2025. Key highlights include the development of oral oncology therapies, particularly BDTX-1535 for non-small cell lung cancer (NSCLC) and glioblastoma, wit", "url": "https://quartr.com/events/black-diamond-therapeutics-bdtx-24th-annual-needham-virtual-healthcare-conference_Fe5VYqZG", "source_name": "Quartr", "published_at": "2026-07-13T06:41:43", "published_display": "13 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment", "summary": "T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 4,028,202 shares of Black Diamond Therapeutics I (BDTX) common stock, which represents a 7.0% stake as of June 30, 2026. The filing specifies that T. Rowe Price holds ", "url": "https://www.stocktitan.net/sec-filings/BDTX/schedule-13g-a-black-diamond-therapeutics-inc-amended-passive-investm-2867a64d67fb.html", "source_name": "Stock Titan", "published_at": "2026-07-08T15:39:17", "published_display": "08 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNN050U0RGVnNjX0dDNTJzOE4xaEM2Q2FxQ3BFMU5VV2laaVBrN3hfMjRwODFCMlJDUGZpREZFZHlzZGgyZGxDM3VDVFBnT3U4VzF1eWZBUUlEdmVNSTVod2NyS0VKYUZUSWlFeWVEc3FqVmI1aTctbl95cXJuSWZ1ZXpNb3BmeVlnT1pJeUpQS0dmcWpmaEJwWmdxdkhOSTk3dkFFS2ZaNmk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article analyzes Black Diamond Therapeutics Inc.'s (BDTX) financial performance, focusing on its profitability and market position. It highlights the company's undefined gross, operating, and net margins, alongside a Return on Equity (ROE) of -35.16%. The analysis also inclu", "url": "https://intellectia.ai/en/stock/BDTX/financials", "source_name": "Intellectia AI", "published_at": "2026-07-04T04:39:55", "published_display": "04 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 32, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDTX SEC Filings - Black Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Black Diamond Therapeutics (BDTX) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms (Form 4). Recent filings highlight director stock compensation in lie", "url": "https://www.stocktitan.net/sec-filings/BDTX/page-4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:10:19", "published_display": "01 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali", "summary": "This article reports a statement of changes in beneficial ownership of securities for Director Behbahani Ali at Black Diamond Therapeutics. This indicates a filing related to insider trading or changes in stock holdings by a company director.", "url": "https://www.moomoo.com/news/notice/306711005/black-diamond-therapeutics-4-statement-of-changes-in-beneficial-ownership", "source_name": "Moomoo", "published_at": "2026-07-01T10:12:12", "published_display": "01 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash", "summary": "This document is a statement of changes in beneficial ownership of securities for Raman Prakash, a Director at Black Diamond Therapeutics. It details changes in his holdings, as required by regulatory bodies.", "url": "https://www.moomoo.com/news/notice/306710932/black-diamond-therapeutics-4-statement-of-changes-in-beneficial-ownership", "source_name": "Moomoo", "published_at": "2026-06-30T22:09:24", "published_display": "30 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity", "summary": "Black Diamond Therapeutics director Raman Prakash received a grant of 40,000 stock options with an exercise price of $1.71 per share, expiring on June 25, 2036. The options will vest fully on the earlier of June 26, 2027, or the company's next annual meeting, provided Prakash rem", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-624b4014d370.html", "source_name": "Stock Titan", "published_at": "2026-06-30T09:09:09", "published_display": "30 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond (BDTX) director awarded 40,000 stock options at $1.71", "summary": "Black Diamond Therapeutics director Ali Behbahani was granted 40,000 stock options at an exercise price of $1.71 per share, set to expire on June 25, 2036. These compensation awards will vest on the earlier of June 26, 2027, or the company's next annual meeting, provided Behbahan", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-49422efa8e65.html", "source_name": "Stock Titan", "published_at": "2026-06-29T22:09:24", "published_display": "29 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) 2026 meeting backs directors, auditor and annual say-on-pay", "summary": "Black Diamond Therapeutics (BDTX) held its 2026 annual shareholder meeting where stockholders elected Shannon Campbell and Kapil Dhingra as Class III directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending Decembe", "url": "https://www.stocktitan.net/sec-filings/BDTX/8-k-black-diamond-therapeutics-inc-reports-material-event-518692486751.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:10:24", "published_display": "29 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com", "summary": "This article reports on a Form 4 filing for Black Diamond Therapeutics Inc. on June 29. It includes the stock symbol BDTX and its current performance (+2.34%). The content primarily shows a stock market overview with various financial data.", "url": "https://ca.investing.com/news/stock-market-news/form-4-black-diamond-therapeutics-inc-for-29-june-93CH-4712536", "source_name": "Investing.com Canada", "published_at": "2026-06-29T21:09:09", "published_display": "29 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71", "summary": "Samarth Kulkarni, a director at Black Diamond Therapeutics (BDTX), was granted stock options for 40,000 shares of common stock with an exercise price of $1.71 per share. These options are set to vest on the earlier of June 26, 2027, or the company's next annual meeting, contingen", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-be22c0474bdb.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:09:09", "published_display": "29 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) awards 40,000-share option grant", "summary": "Black Diamond Therapeutics director Shannon Campbell was granted stock options for 40,000 shares of common stock with an exercise price of $1.71 per share, expiring on June 25, 2036. The options will vest on the earlier of June 26, 2027, or the company\u2019s next annual meeting, prov", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-d70612b418a7.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:09:09", "published_display": "29 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 2000 Index", "summary": "Black Diamond Therapeutics, Inc. (NasdaqGS:BDTX) has been added to the Russell 2000 Index, a significant development for the clinical-stage oncology company. This inclusion follows several recent updates, including positive Phase 2 results for their drug Silevertinib and addition", "url": "https://www.marketscreener.com/news/black-diamond-therapeutics-inc-nasdaqgs-bdtx-added-to-russell-2000-index-ce7f5fdfda8cf021", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:40:54", "published_display": "29 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark", "summary": "Black Diamond Therapeutics, Inc. (NasdaqGS:BDTX) has been added to the Russell 2000 Value Benchmark, as reported on June 29, 2026. This inclusion is part of a series of recent index additions and removals for the company, including being added to the Russell 2000 Index and Russel", "url": "https://www.marketscreener.com/news/black-diamond-therapeutics-inc-nasdaqgs-bdtx-added-to-russell-2000-value-benchmark-ce7f5fdfd88afe21", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:23:00", "published_display": "29 Jun 2026 11:23", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 3000E Index", "summary": "Black Diamond Therapeutics, Inc. (NasdaqGS: BDTX) has been added to the Russell 3000E Index. The company, a clinical-stage oncology firm, focuses on developing MasterKey therapies for various oncogenic mutations in cancer patients, including its BDTX-1535 drug for NSCLC and gliob", "url": "https://www.marketscreener.com/news/black-diamond-therapeutics-inc-nasdaqgs-bdtx-added-to-russell-3000e-index-ce7f5fdedd81f420", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:40:08", "published_display": "29 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Black Diamond Therapeutics, Inc. \u2013 NASDAQ:BDTX", "summary": "The article focuses on the enterprise value to EBITDA forward for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). It indicates that the company's market is currently closed with no trades. The content primarily lists navigational elements and financial data sources provided by v", "url": "https://www.tradingview.com/symbols/NASDAQ-BDTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:40:08", "published_display": "29 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Black Diamond Therapeutics, Inc. \u2013 BOATS:BDTX", "summary": "The article focuses on the \"Price to book forward\" metric for Black Diamond Therapeutics, Inc. (BDTX), listed on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data page from TradingView, displaying no actual data but providing context for where suc", "url": "https://www.tradingview.com/symbols/BOATS-BDTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:54", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Black Diamond Therapeutics, Inc. \u2013 BOATS:BDTX", "summary": "This article provides financial information for Black Diamond Therapeutics, Inc. (BDTX) via TradingView. It specifically focuses on the company's price to sales forward metric. The content is part of a larger financial data platform.", "url": "https://www.tradingview.com/symbols/BOATS-BDTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:38", "published_display": "26 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) AGM 2026 Summary", "summary": "This article provides a summary of Black Diamond Therapeutics (BDTX) 2026 Annual General Meeting (AGM). The virtual meeting addressed formal business, corporate governance, and voting procedures, confirming a quorum with nearly 78% shareholder representation. The summary highligh", "url": "https://quartr.com/events/black-diamond-therapeutics-inc-bdtx-agm-2026_Fe5VPE4o", "source_name": "Quartr", "published_at": "2026-06-26T17:10:41", "published_display": "26 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Black Diamond Therapeutics, Inc. \u2013 NASDAQ:BDTX", "summary": "This article displays the \"Price to sales forward\" metric for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). The content appears to be a stub or a section from a larger financial data platform, showing the stock ticker and market information without detailed financial figures o", "url": "https://www.tradingview.com/symbols/NASDAQ-BDTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:57", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Black Diamond Therapeutics, Inc. \u2013 NASDAQ:BDTX", "summary": "This article focuses on the enterprise value to EBIT forward ratio for Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The content highlights the specific financial", "url": "https://www.tradingview.com/symbols/NASDAQ-BDTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:42:16", "published_display": "26 Jun 2026 02:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Black Diamond Therapeutics, Inc. \u2013 BOATS:BDTX", "summary": "This article focuses on the price-to-earnings forward metric for Black Diamond Therapeutics, Inc. (BDTX), listed under the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data page from TradingView, providing an overview of the company's financial inform", "url": "https://www.tradingview.com/symbols/BOATS-BDTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:42:16", "published_display": "26 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Black Diamond Therapeutics Inc For: 22 June By Investing.com", "summary": "This article announces the filing of Form 4 for Black Diamond Therapeutics Inc. on June 22nd, as reported by Investing.com. It is a brief, one-sentence news piece from an investing news platform. The content primarily focuses on the regulatory filing for the specified company on ", "url": "https://ng.investing.com/news/stock-market-news/form-4-black-diamond-therapeutics-inc-for-22-june-93CH-2568528", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T06:39:38", "published_display": "23 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ali Behbahani of Black Diamond (NASDAQ: BDTX) receives 8,961-share award", "summary": "Ali Behbahani, a director at Black Diamond Therapeutics (NASDAQ: BDTX), was granted 8,961 shares of common stock valued at $1.66 per share. This award was part of the company's non-employee director compensation policy, allowing him to elect stock in lieu of cash for his annual b", "url": "https://www.stocktitan.net/sec-filings/BDTX/form-4-black-diamond-therapeutics-inc-insider-trading-activity-c7ce2d383942.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:40:20", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Black Diamond Therapeutics Inc (BDTX) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The article also presents current stock perf", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:07", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Inc (BDTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "Black Diamond Therapeutics Inc (BDTX) currently has a price momentum score of 6.58, ranking 228th in its industry. The stock is trading between a resistance level of 3.21 and a support level of 0.90, making it suitable for range-bound swing trading. Technical indicators and movin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdtx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:41", "published_display": "17 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes the valuation of Black Diamond Therapeutics Inc (BDTX), noting its current valuation score of 6.68, which places it in the lower rankings within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.19, indicating a signi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T15:39:55", "published_display": "16 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path", "summary": "The article discusses Black Diamond Therapeutics' promising lung cancer data for its drug Silevertinib. The company is evaluating its FDA approval pathway based on these results.", "url": "https://www.msn.com/en-us/health/other/black-diamond-therapeutics-touts-silevertinib-lung-cancer-data-eyes-fda-path/ar-AA24Z84P", "source_name": "MSN", "published_at": "2026-06-13T01:40:00", "published_display": "13 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Stock Outlook After Q1 Beat and Cash Runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRFZIZGU5TkVfLTUxbnRYVWlDcjRnLTRvbnVrUF85VUV2MHdtdG5COV9XY2ZaYVlSbHpzN0lldmUyWS1UaVZ5aHlmQkU4OThaQXpxRVk2VUo5ZUJ3YXZ3ckJ0Mlk1RXhhYm1fOUN6R3BQMHpLc2dWYk1OVWJORWljcTBKZm9qU243Z3RnSXNVeHpJMjZLOXJweTdJaw?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/black-diamond-therapeutics-participate-jefferies-120000523.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T12:00:00+00:00", "published_display": "22 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study", "summary": "", "url": "https://finance.yahoo.com/m/3bca08cd-03ae-38d2-b343-d6661fcfbf84/black-diamond-therapeutics.html", "source_name": "MarketBeat", "published_at": "2026-05-21T23:09:11+00:00", "published_display": "21 May 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/black-diamond-therapeutics-announces-positive-211300750.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:13:00+00:00", "published_display": "21 May 2026 21:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Announces Encouraging Phase 2 Trial Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxOV3F4Ulpkcl80eEt6TTVxUWVVSVh1ZzZZeEg2akNoT0V3Qk02anp5SWpqSkplOHBKOFByM1E4OUhEcW01XzZXazRiRm9YVExXY0k4eWdyOHpCNzJENkRWY2NtdTdsZUtmOUlEckxSVjYyT1Rtb1NIbGZOOG10ajVCelExRms0dHFQeTZkWGhtNkpmNkxhYlF2S1NoRmdWM3FEcmlNd0FTbkZmYnBuNElkY1BpMmdZaE8zaXp3RnEtd2FMc2ZkbVdNeW1vTW9FV0pOa2ZUSXU1S1NESlVYclhjTkExd040QWE5UkRlMkRWbFlBZlVHbnJuay1mamNQQ2pjWHRNSWZwUzhCaTNkTVFR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/black-diamond-therapeutics-host-webcast-120000895.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T12:00:00+00:00", "published_display": "19 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNdjZCVlZ4Y0RfR1N0RFlJaFY3QXpES1NrRDhBbkxCNFFEeXNLNjhCUkJwTUtnUTg2MnlKMG9CRVhkT1IyZW9VVXJWdThVVkhVY0I4aC1jV0lTRksxdU1xRzBET1N1Sm5JTnJFSWdsNkJyQ2xEcFhIejNRVXdLQzJwUklfQnBqOU5EXy0tWmdXN2FmdGlhY3ZNNXp4ZHlsMW1NOGphWEZ3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZ2hGREgxYVJWVk1JQ1hsLXdqZUNQeXk5WEJrS2VzTkluVjAtTnpYS0NqWFluU3JQTzJWNFhiUmNXa285eV9hN2wwNDJxWHNfbUpSUXE5UkVmV0Z3a3JwUWE3STJseWJuTC03UzhkLUVjSGRCclRUT2FoenFOUTl0RGdQeEpOaHNaSk9TSzBhb3NjcmZYOUNxa1NKUGZkSjFQNjZ0bmFrVlZUUmdDbnc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics Announces Multiple Presentations on Silevertinib at 2026 ASCO Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPN2VyLTRDeWp6MUhBUjBCMmZUOFdjdmY0RWxSMG1FMjh2WUl2VE55VkNLenJaSC1TVG5zVC1XTW9pbHJhZXpWNUFDVWJsY3U4UWp0aHlPdDB4a0ZNdmhrUzFrQ3NabktNNWtISmY4QzZlY19zUlRHRXYwbjctWnRqY2pfM0VoNVM4VmdXdHR4R2w1VWRyMUFHbWVlN05rOFpLUGxGVjlfeERaUEhoZkFaUHF5a2JPb1Fpa28wZlNrcFY4NzUxaGtFRUgyd1pKVmxTeXc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lung cancer drug data from Black Diamond gets ASCO oral slot", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPQjNrbVVHZjZjM2hoVFhLOW5ReXJRTzI1UXZkOTNkNUZSX3lwMEZrVHRBUFY2M292bGhIdU4xRmRKY1FOaXpvUUNCWFZpN0NZdTJmVGcyR1FzS3NTel9lNWpjazhkZ2R0RDdPX3J0R1FFTXpOYUM5bkJfd0lEa0hsQzR2Z051aXlWRUhnMWtQVTBkV19sem5Xczg5V1h5dVF5T21MUVU5emdiZ3ZreFF5cEFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNQW9IRWttYWtPT1FXMkdORFQ4SkpBd1ZheXBoZERoTy03blRJT1J5bnZtc3N3T1hqS0I5TFdYX3A2djVOLTFBVWlGaUxMQUZqYU1VVTBaTXh1cTZCV05EVFk2eVhXUjhPYjNNR3BXZWxsd1c3MEY0aXhaOTlTbHF6bzdFcjFzNGFWVDdQM0FVdVFlM2lD?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOQW9hdGdPTVh3bTc1YW9UcGNFV1NSX3hTc01GZDl0N29Ha3RyTWRGdzBqODdqR3EtczR5UGJnbFE3QzBQMnNTWncyX1NXWVhZTm9zZUR6ZDJPQUxKTExnZkJlbnE1WXNhOTR4WEFocXc4ak9QQ2hlLWFsbkgzRVFDTHp6TGc3dlJmUFA5YkNSNkhhSXJ1SE9xWUdZYVF5bms0bVlkU0dTdnJlRU52Q2lWWA?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNMmthcTJ6TzlVdm5DckFfbEF6WkdWV21KaE9jcW53U0JfY29JeUgwTkZXRGhYWVRMa2dyV05sWGRYcVc3V1Yyb2d5WnVLbXpuRXBITndzVDdxelp0bFVuLXM2VHZ3UVEzOFI3SUUtTDlJTXphakRPVVVQZ0lGYzBzSzlLM3ZfOWZC?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Black Diamond (BDTX) a New Strong Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPa01mX3FPZzJqZV92a0JjMEdNTG5CWEVhUGZZemNwc28yWWxfNlBCdmE1WncyOHVsM19GYzNIbmhsTS10bmxCelU5V1hXMmZpVGVNU1RWZlRJUlpCTFZVT3FBS2lEVmQ5dUtDTEZZemhQQ2lINHYxbnlyQzhKb0c4US1OOA?oc=5", "source_name": "Market source", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5nVmVxNVVNbTYwaGN1UlJMd0lGeEM5RkF1MEc1RmxmZjdsbVYwdno5bzFlMlhsYlBCWXJ4OWt0UFpRRU5OS1B6Uy1tcTJPdUxFWWR6cUJ4Q3lUZTZ0RlY4Q2ZSMTQ4N0luM3MwZ0g2LVA?oc=5", "source_name": "Market source", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNaUxIaXUtSUJRRDA5dlIxdXgwdEZUMkZTMHBoZjVTWjVEVkdGM1RmazhTTVZESzBTbEJNSWVnUzk0cFhrUlZoTHJKY1ZNT08tWHNCQW9USVBvYzdMdmdiUW5hVDlST1BQQXh4VkgzRXVwTlpReUtIWGxZeWFHODBFTWEtbkhfZlk1blRtRA?oc=5", "source_name": "Market source", "published_at": "2025-08-18T07:00:00+00:00", "published_display": "18 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFB5LWNvTGpCRW5vbTQ0NFl2MWR4Um1tV3NOakVDY2FKNFRDS2NqNE8tTXBsWXRmY2IzYlY3cGpac1c3djRmLTlSUWFtVUk5amtObTM0R3B1TzJQeFdGY0xuZURHZzN2QXV1?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T17:05:23+00:00", "published_display": "09 Jul 2025 17:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBSWVVRWTNEN0FsNmJickxrVkRiUGR0eDIwSkF1Sm5jMVVTUklrRURfeXRkWkZJaFludU81dE9RTVZGcTlZR2ZlSnVOLVgySkxVREV3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:15:37+00:00", "published_display": "25 Apr 2025 01:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Black Diamond Therapeutics: Is Now the Time to Buy or Run Away?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQR2NpbUtENURkYmRnVXhKZmtqSUdURWxXSTVNNEFpUmhmMXFMX2dSdDRzZHFjcElhaXVTNzdtMXlVQUlkbWlZZHJNdFB1Tm1odHpxMk90cGt2NFdBVnFQVzBWeGsydFVFM3BhR20xaUxsT0JLZmo4cnFLR2VDeThZRmRxdFVYZnVLTGRxOG53YVlGUQ?oc=5", "source_name": "timothysykes.com", "published_at": "2024-09-23T07:00:00+00:00", "published_display": "23 Sep 2024 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 61, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 42, "score": 54, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 10.11, "count": 20}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.91, "latest_week": "2026-07-10", "one_week_move": -5.0, "four_week_move": 9.1, "twelve_week_move": -37.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.532091, "market_dynamics_buy_signal": false, "relative_strength": -41.33162, "fair_value_gap": -40.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.0227, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.0% over one week, +9.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 7}, {"label": "simplywall.st", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Quartr", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 20}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.0% over one week, +9.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview"}], "updated_at": "2026-07-17T22:38:06.064066+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}